(BUSINESS WIRE)–Jan. 22, 2015– ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. Thomas J. DesRosier, Esq. joins ARIAD as executive vice president, chief legal and administration officer, and secretary. (Photo: Business Wire) Mr. DesRosier… Read more »
Shares of Ariad Pharmaceuticals closed yesterday at $6.12 . ARIA has a 1-year high of $9.83 and a 1-year low of $4.90. The stock’s 50-day moving average is $6.74 and it’s 200-day moving average is $6.09.
On the ratings front, Ariad Pharmaceuticals has been the subject of a number of recent research reports. In a report published on January 13, analyst Cory Kasimov from J.P. Morgan maintained a Hold rating on ARIA. Separately, on the same day, Cowen`s Phil Nadeau maintained a Hold rating on Ariad Pharmaceuticals shares and has a price target of $4.50.
In total, one research analyst has rated the stock with a Sell rating, one research analyst has assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $6.12 which is 0.8% above where the stock closed yesterday.
Ariad Pharmaceuticals Inc is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.